Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
1983 1
1986 1
1988 1
1989 1
1992 3
1995 3
1996 3
1997 2
1998 1
1999 2
2000 1
2002 2
2004 1
2005 2
2006 5
2007 3
2008 1
2009 2
2010 7
2011 7
2012 8
2013 5
2014 10
2015 20
2016 10
2017 22
2018 27
2019 10
2020 9
2021 15
2022 19
2023 18
2024 6

Text availability

Article attribute

Article type

Publication date

Search Results

190 results

Results by year

Filters applied: . Clear all
Page 1
Efficacy and safety of first-line lorlatinib versus crizotinib in patients with advanced, ALK-positive non-small-cell lung cancer: updated analysis of data from the phase 3, randomised, open-label CROWN study.
Solomon BJ, Bauer TM, Mok TSK, Liu G, Mazieres J, de Marinis F, Goto Y, Kim DW, Wu YL, Jassem J, López FL, Soo RA, Shaw AT, Polli A, Messina R, Iadeluca L, Toffalorio F, Felip E. Solomon BJ, et al. Among authors: bauer tm. Lancet Respir Med. 2023 Apr;11(4):354-366. doi: 10.1016/S2213-2600(22)00437-4. Epub 2022 Dec 16. Lancet Respir Med. 2023. PMID: 36535300 Clinical Trial.
There were no new safety signals. INTERPRETATION: These updated, long-term data from CROWN show the durable benefit of lorlatinib over crizotinib in patients with treatment-naive, ALK-positive non-small-cell lung cancer and support the use of first-line lorlatinib in patie …
There were no new safety signals. INTERPRETATION: These updated, long-term data from CROWN show the durable benefit of lorlatinib ove …
A randomised, blinded, trial of clopidogrel versus aspirin in patients at risk of ischaemic events (CAPRIE). CAPRIE Steering Committee.
CAPRIE Steering Committee. CAPRIE Steering Committee. Lancet. 1996 Nov 16;348(9038):1329-39. doi: 10.1016/s0140-6736(96)09457-3. Lancet. 1996. PMID: 8918275 Clinical Trial.
BACKGROUND: Many clinical trials have evaluated the benefit of long-term use of antiplatelet drugs in reducing the risk of clinical thrombotic events. ...There were ten (0.10%) patients in the clopidogrel group with significant reductions in neutrophils (< 1.2 x 10(9)/L …
BACKGROUND: Many clinical trials have evaluated the benefit of long-term use of antiplatelet drugs in reducing the risk of clinical t …
Number and Station of Lymph Node Metastasis After Curative-intent Resection of Intrahepatic Cholangiocarcinoma Impact Prognosis.
Zhang XF, Xue F, Dong DH, Weiss M, Popescu I, Marques HP, Aldrighetti L, Maithel SK, Pulitano C, Bauer TW, Shen F, Poultsides GA, Soubrane O, Martel G, Koerkamp BG, Itaru E, Lv Y, Pawlik TM. Zhang XF, et al. Among authors: bauer tw. Ann Surg. 2021 Dec 1;274(6):e1187-e1195. doi: 10.1097/SLA.0000000000003788. Ann Surg. 2021. PMID: 31972643
OBJECTIVES: To determine the prognostic implication of the number and station of LNM, and the minimal number of LNs needed for evaluation to accurately stage patients with intrahepatic cholangiocarcinoma (ICC). BACKGROUND: Impact of the number and station of LNM on long-term …
OBJECTIVES: To determine the prognostic implication of the number and station of LNM, and the minimal number of LNs needed for evaluation to …
Axenic Long-Term Cultivation of Pneumocystis jirovecii.
Riebold D, Mahnkopf M, Wicht K, Zubiria-Barrera C, Heise J, Frank M, Misch D, Bauer T, Stocker H, Slevogt H. Riebold D, et al. Among authors: bauer t. J Fungi (Basel). 2023 Sep 1;9(9):903. doi: 10.3390/jof9090903. J Fungi (Basel). 2023. PMID: 37755011 Free PMC article.
Pneumocystis jirovecii, a fungus causing severe Pneumocystis pneumonia (PCP) in humans, has long been described as non-culturable. Only isolated short-term experiments with P. jirovecii and a small number of experiments involving animal-derived Pneumocystis species have be …
Pneumocystis jirovecii, a fungus causing severe Pneumocystis pneumonia (PCP) in humans, has long been described as non-culturable. Only isol …
Benchmarks in Liver Resection for Intrahepatic Cholangiocarcinoma.
Alaimo L, Endo Y, Catalano G, Ruzzenente A, Aldrighetti L, Weiss M, Bauer TW, Alexandrescu S, Poultsides GA, Maithel SK, Marques HP, Martel G, Pulitano C, Shen F, Cauchy F, Koerkamp BG, Endo I, Kitago M, Pawlik TM. Alaimo L, et al. Among authors: bauer tw. Ann Surg Oncol. 2024 May;31(5):3043-3052. doi: 10.1245/s10434-023-14880-8. Epub 2024 Jan 12. Ann Surg Oncol. 2024. PMID: 38214817 Free PMC article.
The postoperative benchmark values included TOO achievement 59.3%, positive resection margin 27.5%, 30-day readmission 3.6%, Clavien-Dindo III or more complications 14.3%, and 90-day mortality 4.8%, as well as hospital stay 14 days. CONCLUSIONS: Benchmark cutoffs targeting short- …
The postoperative benchmark values included TOO achievement 59.3%, positive resection margin 27.5%, 30-day readmission 3.6%, Clavien-Dindo I …
Long-term surveillance of branch-duct intraductal papillary mucinous neoplasms without worrisome or high-risk features.
Lattimore CM, Kane WJ, Subbarao S, Venitti C, Cramer CL, Turkheimer LM, Bauer TW, Turrentine FE, Zaydfudim VM. Lattimore CM, et al. Among authors: bauer tw. J Surg Oncol. 2023 Dec;128(7):1087-1094. doi: 10.1002/jso.27414. Epub 2023 Aug 2. J Surg Oncol. 2023. PMID: 37530526
INTRODUCTION: Long-term data evaluating clinical outcomes in patients with branch-duct Intraductal papillary mucinous neoplasms (BD-IPMN) without high-risk stigmata (HRS) or worrisome features (WF) remain limited. ...
INTRODUCTION: Long-term data evaluating clinical outcomes in patients with branch-duct Intraductal papillary mucinous neoplasms (BD-I …
T cell receptor grafting allows virological control of Hepatitis B virus infection.
Wisskirchen K, Kah J, Malo A, Asen T, Volz T, Allweiss L, Wettengel JM, Lütgehetmann M, Urban S, Bauer T, Dandri M, Protzer U. Wisskirchen K, et al. Among authors: bauer t. J Clin Invest. 2019 Apr 30;129(7):2932-2945. doi: 10.1172/JCI120228. J Clin Invest. 2019. PMID: 31039136 Free PMC article.
Co-treatment with the entry inhibitor Myrcludex B ensured long-term control of HBV infection. Thus, T cells stably transduced with highly functional TCRs have the potential to mediate clearance of HBV-infected cells causing limited liver injury....
Co-treatment with the entry inhibitor Myrcludex B ensured long-term control of HBV infection. Thus, T cells stably transduced with hi …
Cardiac Rehabilitation Reduces 2-Year Mortality After Coronary Artery Bypass Grafting.
Bauer TM, Yaser JM, Daramola T, Mansour AI, Ailawadi G, Pagani FD, Theurer P, Likosky DS, Keteyian SJ, Thompson MP. Bauer TM, et al. Ann Thorac Surg. 2023 Nov;116(5):1099-1105. doi: 10.1016/j.athoracsur.2023.05.044. Epub 2023 Jun 29. Ann Thorac Surg. 2023. PMID: 37392993 Free PMC article.
This statewide analysis of patients undergoing CABG evaluated the relationship between CR use and long-term mortality. METHODS: Medicare fee-for-service claims were linked to surgical data for patients discharged alive after isolated CABG from January 1, 2015, through Sept …
This statewide analysis of patients undergoing CABG evaluated the relationship between CR use and long-term mortality. METHODS: Medic …
Mesiotemporal Volumetry, Cortical Thickness, and Neuropsychological Deficits in the Long-term Course of Limbic Encephalitis.
Harms A, Bauer T, Witt JA, Baumgartner T, von Wrede R, Racz A, Ernst L, Becker AJ, Helmstaedter C, Surges R, Rüber T. Harms A, et al. Among authors: bauer t. Neurol Neuroimmunol Neuroinflamm. 2023 May 25;10(4):e200125. doi: 10.1212/NXI.0000000000200125. Print 2023 Jul. Neurol Neuroimmunol Neuroinflamm. 2023. PMID: 37230543 Free PMC article.
190 results